Figure 4.

Identification of the potential target patient subset for BsAb5003. GPRC5D mRNA expression based on (a) treatment backgrounds, (b) ISS, and (c) genetic abnormalities in CD138 + cells sorted from BMMNCs derived from 26 patients. The samples which have been treated with a certain SoC or the presence or absence of high-risk genetic abnormality are classified in “+”, and that which have not been are in “−” (a,c). The samples which were newly diagnosed and have been treated with no treatment, that which have been with 1 regimen, that with 2 regimens, or that with 3 or more regimens are classified as “ND”, “1”, “2”, “L >  = 3”, respectively (b). The horizontal bar indicates median value. Statistical significance was determined by a two tailed t-test (*P < 0.05).